| Date | Title | Description |
| 14.08.2025 | Kuros achieves first ever operating profit in H1 |
The total group revenue reached USD 63.5 million, marking a growth of 78% compared to H1 2024. The company achieved an operating profit of USD 3.5 million in the first half of 2025, marking its first positive operating result, up from an o... |
| 15.04.2025 | Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 | Ad hoc announcement pursuant to Article 53 of the SIX listing rules
Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025
Financial & Operational Highlights Direct MagnetOs™ sales increased by ... |
| 11.03.2025 | Kuros Biosciences grows sales to CHF 75.6 million for 2024 | Ad-hoc announcement pursuant to Article 53 of the SIX listing rules
Kuros Biosciences grows sales to CHF 75.6 million for 2024
Financial Highlights Direct MagnetOs™ sales increased by 136% to CHF 74.8 million (2023: CHF 31.7 million)Total M... |
| 16.09.2022 | Kuros Biosciences raises CHF 6.0 million in private placement | |
| 02.06.2022 | Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment | Ad-hoc announcement pursuant to Article 53 of the SIX listing rules
• $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement
SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (... |
| 03.02.2022 | Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications | Kuros Biosciences AG / Key word(s): Miscellaneous
Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
03.02.2022 / 07:00
Rare clearance for bone graft for standalone use in spine based on human clinical data... |
| 03.02.2022 | Kuros Biosciences : Press Release, 3 February 2022 | Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
Rare clearance for bone graft for standalone use in spine based on human clinical data
Clearance attained with evidence from Level 1 randomized controlled ... |
| 03.02.2022 | Kuros Biosciences's MagnetOs Granules Cleared by FDA for Expanded Spinal Indications | Rare clearance for bone graft for standalone use in spine based on human clinical dataClearance attained with evidence from Level 1 randomized controlled trialPositions MagnetOs above most other 510(k)-cleared bone grafts on the market
SCHL... |
| 03.02.2022 | Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications | Rare clearance for bone graft for standalone use in spine based on human clinical dataClearance attained with evidence from Level 1 randomized controlled trialPositions MagnetOs above most other 510(k)-cleared bone grafts on the market
SCHL... |
| 26.10.2021 | Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales | MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020
Kuros expanding MagnetOs range to increase perioperative solutions for surgeons
SCHLIEREN (ZURICH), Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or ... |
| 09.09.2021 | Kuros Biosciences : Press Release, 9 September 2021 | Kuros Biosciences Announces FDA 510(k) Clearance for MagnetOs Easypack PuttyHeadline
Schlieren (Zurich), Switzerland, 9 September, 2021 - Kuros Biosciences ('Kuros' or the 'Company'), a leader in next generation bone graft technologies, ann... |
| 11.08.2021 | Kuros Biosciences : Interim Results, 2021 | Image: MagnetOs' unique submicron surface topography NeedleGripTM
Interim Report
as of June 30, 2021
Table of contents
KEY DEVELOPMENTS ........................................................................................................... |
| 22.06.2021 | Kuros Biosciences : Press Release, 22 June 2021 | Kuros Biosciences announces publication of data on MagnetOs in eCM Journal linking MOA to enhanced predictable bone regeneration
First peer-reviewed article with demonstrated efficacy in preclinical and clinical studies
Outlines ability of ... |
| 08.04.2021 | KUROS BIOSCIENCES AG
Kuros Biosciences : Press Release, 8 April 2021 | Kuros Biosciences announces treatment of first patient in Australia with MagnetOs for spine fusion
First patient treated with MagnetOs outside Europe and U.S.
Augmented pricing status is further validation and opportunity for revenue growth... |
| 08.04.2021 | KUROS BIOSCIENCES AG
Kuros Biosciences : Press Release, 08 April 2021 | Kuros Biosciences announces treatment of first patient in Australia with MagnetOs for spine fusion
First patient treated with MagnetOs outside Europe and U.S.
Augmented pricing status is further validation and opportunity for revenue growth... |
| 08.04.2021 | KUROS BIOSCIENCES AG
Kuros Biosciences announces treatment of first patient in Australia with MagnetOs for spine fusion | Kuros Biosciences announces treatment of first patient in Australia with MagnetOs for spine fusion
First patient treated with MagnetOs outside Europe and U.S.
Augmented pricing status is further validation and opportunity for revenue growth... |
| 18.03.2021 | Kuros Biosciences : Annual Report, 2020 | 2020 Annual Report
"Our focus is on revolutionizing the field of orthobiologics by developing bone grafts that deliver both targeted and controlled bone healing."
Table of content
HIGHLIGHTS OF THE LAST 15 MONTHS .................... |
| 18.03.2021 | KUROS BIOSCIENCES AG
Kuros Biosciences Reports Results for the Full Year 2020 | Financial highlights
CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020Revenues increased by 58% to CHF 4.0 million
Operational highlights Initiated Phase II clinical study of Fibrin-PTH in spineC... |
| 18.03.2021 | KUROS BIOSCIENCES AG
Kuros Biosciences : Annual Report, 2020 | 2020 Annual Report
"Our focus is on revolutionizing the field of orthobiologics by developing bone grafts that deliver both targeted and controlled bone healing."
Table of content
HIGHLIGHTS OF THE LAST 15 MONTHS .................... |
| 18.03.2021 | Kuros Biosciences : Press Release, 18 March 2021 | Kuros Biosciences reports results for the full year 2020
Financial highlights
CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020
Revenues increased by 58% to CHF 4.0 million
Operational highlights... |
| 18.03.2021 | KUROS BIOSCIENCES AG
Kuros Biosciences : Press Release, 18 March 2021 | Kuros Biosciences reports results for the full year 2020
Financial highlights
CHF 29.8 million cash & cash equivalents, trade and other receivables at December 31, 2020
Revenues increased by 58% to CHF 4.0 million
Operational highlights... |
| 10.03.2021 | Kuros Biosciences to Present at Upcoming Clinical and Investor Conferences | New data on the role of osteoimmunology in bone formation at BritSpine Meeting
Investor presentation at BioCapital Europe
SCHLIEREN (ZURICH), Switzerland, March 10, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN), a leader in next ge... |
| 02.03.2021 | Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe | Agreements in Netherlands, Switzerland and Austria and letter of intent in FinlandSupports further acceleration of sales of MagnetOs bone graft
SCHLIEREN (ZURICH), Switzerland, March 02, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN... |
| 20.11.2020 | KUROS BIOSCIENCES AG
Kuros Biosciences : Press Release, 20 November 2020 | Kuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week
Industry-leading award recognizes Kuros' Fibrin-PTH (KUR-113) technology
Rounds off successful year of commercial, clinical, and financial progress
Kuros also win... |
| 20.11.2020 | Kuros Biosciences : Press Release, 20 November 2020 | Kuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week
Industry-leading award recognizes Kuros' Fibrin-PTH (KUR-113) technology
Rounds off successful year of commercial, clinical, and financial progress
Kuros also win... |
| 20.11.2020 | KUROS BIOSCIENCES AG
Kuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week | Kuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week
Industry-leading award recognizes Kuros' Fibrin-PTH (KUR-113) technology
Rounds off successful year of commercial, clinical, and financial progress
Kuros also win... |
| 20.10.2020 | KUROS BIOSCIENCES AG
Kuros Biosciences : Press Release, 19 October 2020 | Not for release, publication or distribution in the USA, the United Kingdom, Canada, Japan, Australia or Member States of the European Economic Area ('EEA').
MEDIA RELEASE
Kuros announces results of Rights Offering
Schlieren (Zurich), Switz... |
| 20.10.2020 | KUROS BIOSCIENCES AG
Kuros Biosciences : Press Release, 20 October 2020 | Not for release, publication or distribution in the USA, the United Kingdom, Canada, Japan, Australia or Member States of the European Economic Area ('EEA')
Kuros announces final result of capital increase - total gross proceeds of CHF 18.6... |
| 19.10.2020 | KUROS BIOSCIENCES AG
Kuros announces results of Rights Offering | Not for release, publication or distribution in the USA, the United Kingdom, Canada, Japan, Australia or Member States of the European Economic Area ("EEA").
MEDIA RELEASE
Kuros announces results of Rights Offering
Schlieren (Zuri... |
| 09.09.2020 | KUROS BIOSCIENCES AG
CORRECTING AND REPLACING -- Kuros Biosciences's Licensee Checkmate Pharmaceuticals Completes its IPO on NASDAQ | SCHLIEREN (ZURICH), Switzerland, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kuros Biosciences corrects gross proceeds raised in first bullet point and second paragraph to $75 million from $86.25 million. Corrected gross proceeds do not include sale... |
| 09.09.2020 | KUROS BIOSCIENCES AG
Kuros Biosciences's licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ | Kuros Biosciences's licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ
Checkmate raises proceeds of $75 million in IPO
Intention to use part of the net proceeds from the IPO to fund the development of its product candidate CMP-0... |
| 09.09.2020 | KUROS BIOSCIENCES AG
Kuros Biosciences's licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ | Total gross proceeds raised by Checkmate in IPO of $86.25 million (including sale of overallotment shares)Intention to use part of the net proceeds from the IPO to fund the development of its product candidate CMP-001, an asset Checkmate ha... |